2321 - Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level

Co-Author(s)

• CC

  Christy A. Comeaux, MD, PhD

  Medical Lead
  Janssen Vaccines & Prevention B.V.
  Leiden, Zuid-Holland, Netherlands

  Disclosure: Disclosure(s): Janssen Vaccines & Prevention B.V.: Employee ()
• 

  Ann R. Falsey, MD

  Dr
  University of Rochester School of Medicine
  Rochester, New York, United States

  Disclosure: Disclosure(s): BioFire Diagnostics: Grant/Research Support (); Janssen: Grant/Research Support (); Merck Sharp & Dohme: Grant/Research Support (); Novavax: Advisor/Consultant (); Pfizer: Grant/Research Support ()
• KW

  Kristi Williams, PhD

  Janssen Research and Development
  Spring House, Pennsylvania, United States

  Disclosure: Disclosure(s): Janssen Research and Development: Employee ()
• SB

  Stephan Bart, MD

  Trial Professional Consultant Group
  Woodstock, Maryland, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• JE

  John E. Ervin, MD

  Principal Investigator
  AMR Kansas City
  Kansas City, Missouri, United States

  Disclosure: Disclosure(s): The Alliance for Multispecialty Research – KCM: Contractual agreement for conduct of study protocol ()

Presenting Author(s)

• 

  Arangassery R. Bastian, PhD

  Biomarker Lead
  Janssen Vaccines & Prevention BV
  Leiden, Zuid-Holland, Netherlands

  Disclosure: Disclosure(s): Janssen Vaccines & Prevention BV: Employee ()

  Slides

Co-Author(s)

• JM

  Joris Menten, PhD

  Janssen Infectious Diseases
  Beerse, Antwerpen, Belgium

  Disclosure: Disclosure(s): Janssen Infectious Diseases: Employee ()
• ED

  Els De Paepe, MSc

  Statistical Lead
  Janssen Infectious Diseases
  Beerse, Antwerpen, Belgium

  Disclosure: Disclosure(s): Janssen Infectious Diseases: employee ()
• SV

  Sjouke Vandenberghe, PhD

  Janssen Infectious Diseases
  Beerse, Antwerpen, Belgium

  Disclosure: Disclosure(s): Janssen Infectious Diseases: Employee ()
• EC

  Eric K. H. Chan, PhD (he/him/his)

  Director, Patient Reported Outcomes
  Janssen Global Services, LLC
  Raritan, New Jersey, United States

  Disclosure: Disclosure(s): Janssen Global Services, LLC: Employee ()
• JS

  Jerald Sadoff, MD

  Senior Advisor, Vaccine Development
  Janssen Vaccines & Prevention BV
  Raritan, New Jersey, United States

  Disclosure: Disclosure(s): Janssen Vaccines & Prevention BV: Employee ()
• MD

  Macaya Douoguih, MD, MPH

  Janssen Vaccines & Prevention B.V.
  Leiden, Zuid-Holland, Netherlands

  Disclosure: Disclosure(s): Janssen Vaccines & Prevention B.V.: Employee ()
• BC

  Benoit Callendret, PhD

  Compound Development Team Leader
  Janssen Vaccines & Prevention B.V.
  Leiden, Antwerpen, Belgium

  Disclosure: Disclosure(s): Janssen Vaccines & Prevention B.V.: Employee ()
• EH

  Esther Heijnen, MD, PhD

  Clinical Franchise Leader, Vaccines
  Janssen Vaccines & Prevention B.V.
  Leiden, Zuid-Holland, Netherlands

  Disclosure: Disclosure(s): Janssen Vaccines & Prevention B.V.: Employee ()